Natco Pharma announced that the Supreme Court dismissed a challenge by F. Hoffmann-La Roche AG regarding the Risdiplam suit. This upholds previous Delhi High Court rulings in Natco’s favor. The decision allows the suit to proceed to trial. The drug, used for Spinal Muscular Atrophy (SMA), offers potential relief to Indian patients where treatment options are limited.
Supreme Court Ruling on Risdiplam
The Supreme Court of India dismissed a challenge by F. Hoffmann-La Roche AG regarding the Risdiplam suit, as announced on October 17, 2025. This decision supports previous rulings by the Delhi High Court that were in favor of Natco Pharma.
Implications for Natco Pharma
The Supreme Court was unconvinced about the maintainability of Roche’s challenge, given the concurrent findings of the Delhi High Court. Consequently, the petition was dismissed. The original suit will now proceed for trial.
Risdiplam and SMA Treatment
Risdiplam is used in the treatment of Spinal Muscular Atrophy (SMA), a condition leading to the degeneration of neurons. This ruling is expected to bring hope to numerous individuals affected by SMA, especially given the limited and often financially inaccessible treatment options currently available in India.
About Natco Pharma
Natco Pharma is an R&D-oriented pharmaceutical company based in Hyderabad, India. They manufacture specialty pharmaceuticals and active pharmaceutical ingredients. The company focuses on oncology and limited competition molecules. Natco has 9 manufacturing sites and 2 R&D facilities, with approvals from several leading regulatory authorities. The company caters to over 50 global markets.
Source: BSE
